NCCN now recommends pemivibart pre-exposure prophylaxis for patients with B-cell lymphomas and other profoundly immunocompromised populations, aligning with IDSA guidance for ages ≥12 years. Humoral ...

For several years, pre-exposure prophylaxis against HIV (PrEP) has been a major success in preventing new cases. However, individuals on PrEP typically engage in riskier sexual behavior and thus are ...

In a far-reaching effort to understand the factors contributing to HIV transmission among sexual and gender minority (SGM) individuals and improve HIV prevention strategies, a team of scientists at ...

The most useful thing about a new HIV-prevention guide may be a question it never asks: Why do you want to know about ...

Pre-exposure prophylaxis (PrEP) has emerged as a transformative biomedical intervention to prevent HIV infection among people at substantial risk. Its adoption reflects a complex interplay of clinical ...

HIV-1 infection remains a major public health problem, with an estimated 38.4 million people living with HIV and 1.5 million new HIV infections reported worldwide in 2021. The risk of HIV infection ...

Pre-exposure prophylaxis (PrEP) employs antiretroviral agents in HIV-negative individuals to avert viral acquisition. Initial efficacy trials of daily oral regimens combining emtricitabine and ...

The EUA was supported by primary data from the phase 3 PROVENT trial. The Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for Evusheld (tixagevimab co-packaged with ...

Background Understanding the ‘real-world’ challenges of delivery of pre-exposure prophylaxis (PrEP) among men who have sex ...

What is Pre-Exposure Prophylaxis (PrEP)? Pre-Exposure Prophylaxis (PrEP) is an HIV prevention strategy that enables HIV-negative people to stay HIV-negative by taking anti-HIV drugs (also called ...